Welcome
Support Centre
24 July 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Combination therapy in rheumatoid arthritis
ISRCTN ISRCTN18445519
DOI 10.1186/ISRCTN18445519
ClinicalTrials.gov identifier
EudraCT number
Public title Combination therapy in rheumatoid arthritis
Scientific title Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a multicentre randomised open parallel-group treatment strategy trial
Acronym FIN-RACo trial
Serial number at source 31.1.1993
Study hypothesis Using the combination of disease modifying anti-rheumatic drugs (DMARDs) (sulphasalazine, hydroxychloroquine, and methotrexate) with low dose prednisolone at very early stage of rheumatoid arthritis may be the better treatment strategy in the induction of remission and improvement of disease clinical activity than single-drug treatment stategy of rheumatoid arthritis.
Lay summary
Ethics approval The Joint Commission on Ethics of the Turku University and the Turku University Central Hospital approved on the 2nd March 1993 (ref: supp 1 § 34)
Study design Multicentre randomised open parallel-group treatment strategy trial
Countries of recruitment Finland
Disease/condition/study domain Rheumatoid arthritis
Participants - inclusion criteria 1. American Rheumatism Association criteria for rheumatoid arthritis
2. Aged between 18 and 65 years, either sex
3. Duration of symptoms of less than 2 years
4. Active disease with three or more swollen joints and at least three of the following:
4.1. Erythrocyte sedimentation rate (ESR) at least 28 mm/h
4.2. C-reactive protein (CRP) above 19 mg/l
4.3. Morning stiffness of 29 minutes or more
4.4. More than five swollen joints
4.5. More than ten tender joints
Participants - exclusion criteria 1. Patients who had used DMARDs in the past
2. Had undergone glucocorticoid therapy within the previous 2 weeks
3. Patients with serious comorbidity
4. Suspected inability to comply with the protocol
5. Hypersensitivity to any study medication
6. A history of cancer
7. Pregnant women
8. Women of childbearing age who were not using reliable methods of contraception
Anticipated start date 30/04/1993
Anticipated end date 28/03/2007
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet (Finnish and Swedish only)
Target number of participants 199
Interventions Combination therapy started with sulphasalazine 500 mg twice daily, methotrexate 7.5 mg weekly, and hydroxichloroquine 300 mg daily, and prednisolone 5 mg daily. This initial combination, if tolerated, was continued for 3 months. If the clinical improvement at 3 months was under 50% in at least two of the three criteria (swollen joints, tender joints, and ESR or CRP), the respective doses of methotrexate and prednisolone were increased to 10 mg weekly and 7.5 mg daily. The protocol allowed flexible subsequent dose adjustment to mimic clinical practice. Thus, the highest dose at 9 months and thereafter was 2 g daily for sulphasalazine, 15 mg weekly for methotrexate, 300 mg daily for hydroxychloroquine, and 10 mg daily for prednisolone. If a patient reached remission during the first year with initial combination, the drug doses were tapered, and prednisolone and methotrexate could even be discontinued at 9 months and 18 months, respectively. Sulphasalazine (1 g daily), and hydroxychloroquine (300 mg daily) had to be continued for 2 years. In the patients who reached remission during the first year, but not with the initial combination, the drug doses were gradually tapered to those of the second year. If the induced remission was lost, the DMARD doses were increased with the intention of reaching remission. If one or several components of the combination had to be discontinued for any reason, a combination of three DMARDs was restarted by replacing sulphasalazine and hydroxychloroquine with auranofin (3 - 6 mg daily), and methotrexate with azathioprine (2 mg/kg daily). Other DMARDs could also be used as substitutes.

The single-treatment strategy was also targeted to achieve remission. The simultaneous use of oral prednisolone up to 10 mg was allowed in patients with continuously active disease, but simultaneous use of multiple DMARDs was not allowed. The decision to use prednisolone was made by the treating physician. The patients were treated continuously with one DMARD alone, with or without prednisolone. If a more beneficial effect was needed, the dose was increased or the DMARD was changed. Sulphasalazine (2 g daily) was used as the initial drug in all patients, and the dose was increase to 3 g daily at 3 months, if clinically indicated. If an adverse event occurred, or if the clinical response was less than 25% at 6 months, the protocol required that sulphasalazine was replaced with methotrexate 87.5 mg - 15 mg weekly).

Intraarticular injections of glucocorticoids into inflamed joints were allowed in both treatment arms.

All the patients were clinically assessed at baseline and at months 1, 3, 4, 5, 6, 9, 12, and 24 and the adjusments of drug doses were performed.

After two years, treatment was still aimed at achieving or maintaining remissions, but the choise and use of DMARDs was unrestricted. Thus, regardless of the original randomisation group, patients who had an insufficient response could be treated liberally with increased dosages of DMARDs (methotrexate up to 25 mg/week) and with DMARD combination when clinically indicated and tolerated.
Primary outcome measure(s) Induction of remission: American College of Rheumatology (ACR) preliminary criteria for remission were used. However, the patient might or might not be using any drug treatment, and fatigue and duration definition were excluded. The patient with remission was not, by definition, one with any swollen or tender joints. Assessed at 6 months, 12 months and thereafter annually for 11 years.
Secondary outcome measure(s) Assessed at 1, 3, 4, 5, 6, 9, 12 months and thereafter annually for 11 years:
1. Proportion of patients achieving a meaningful clinical response (ACR50% response)
2. Development of radiographic joint damage
3. Frequency of adverse effects
4. Physical function (HAQ)
5. Work capacity
Sources of funding All costs are classed as usual treatment and are therefore covered under the Finnish National Health Insurance (NHI) scheme (Finland)
Trial website
Publications 1. 1999 results in http://www.ncbi.nlm.nih.gov/pubmed/10334255
2. 2000 results in http://www.ncbi.nlm.nih.gov/pubmed/11083260
3. 2002 results in http://www.ncbi.nlm.nih.gov/pubmed/11953964
4. 2004 results in http://www.ncbi.nlm.nih.gov/pubmed/15248204
5. 2005 results in http://www.ncbi.nlm.nih.gov/pubmed/15641055
6. 2009 results in http://www.ncbi.nlm.nih.gov/pubmed/19404945
Contact name Prof  Timo  Möttönen
  Address TYKS, Paimio Hospital
Alvar aalto way 275
  City/town Paimio
  Zip/Postcode 21540
  Country Finland
Sponsor Turku University Hospital (Finland)
  Address Kiinamyllykatu 4-8
  City/town Turku
  Zip/Postcode 20520
  Country Finland
  Sponsor website: http://www.vsshp.fi
Date applied 13/11/2009
Last edited 27/11/2009
Date ISRCTN assigned 27/11/2009
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.